Top Reasons Therapies Not Offered by HCPs in the US^1,a

In the US, financial challenges were noted as the most common reason as to why BsAbs or CAR T-cell therapy were not offered to patients

^aTop reason defined as any reason that was given by more than 25% of HCPs during the survey.

BsAb, bispecific antibody; CAR, chimeric antigen receptor; HCP, health care professional.

Reference

1. Zamagni E, Kevin B, Cormier N, et al. Differences across countries in healthcare provider confidence with CAR-T and bispecific antibody therapies for relapsed/refractory multiple myeloma. Presented at: EHA 2025 Congress; June 12-15, 2025; Milan, Italy. Poster PS1751.